Akero Therapeutics Balance Sheet Health
Financial Health criteria checks 5/6
Akero Therapeutics has a total shareholder equity of $535.3M and total debt of $25.0M, which brings its debt-to-equity ratio to 4.7%. Its total assets and total liabilities are $580.3M and $45.0M respectively.
Key information
4.7%
Debt to equity ratio
US$24.96m
Debt
| Interest coverage ratio | n/a |
| Cash | US$550.01m |
| Equity | US$535.31m |
| Total liabilities | US$44.97m |
| Total assets | US$580.27m |
Recent financial health updates
We're Not Very Worried About Akero Therapeutics' (NASDAQ:AKRO) Cash Burn Rate
May 04
We Think Akero Therapeutics (NASDAQ:AKRO) Can Afford To Drive Business Growth
Jan 15Akero Therapeutics (NASDAQ:AKRO) Is In A Good Position To Deliver On Growth Plans
Oct 01Akero Therapeutics (NASDAQ:AKRO) Is In A Good Position To Deliver On Growth Plans
Jun 10Recent updates
Akero Therapeutics' EFX Data Warrants Caution
Apr 03Akero: Phase 2b NASH Data Bodes Well For Phase 3 SYNCHRONY Program
Mar 04Akero Therapeutics announces closing of upsized public offering
Sep 19Akero adds over 100% rallying peers after NASH success
Sep 13We're Not Very Worried About Akero Therapeutics' (NASDAQ:AKRO) Cash Burn Rate
May 04We Think Akero Therapeutics (NASDAQ:AKRO) Can Afford To Drive Business Growth
Jan 15Akero Therapeutics (NASDAQ:AKRO) Is In A Good Position To Deliver On Growth Plans
Oct 01Akero: Ticking All The Right Boxes In NASH
Sep 23Akero Therapeutics (NASDAQ:AKRO) Is In A Good Position To Deliver On Growth Plans
Jun 10Financial Position Analysis
Short Term Liabilities: AKRO's short term assets ($560.0M) exceed its short term liabilities ($19.1M).
Long Term Liabilities: AKRO's short term assets ($560.0M) exceed its long term liabilities ($25.8M).
Debt to Equity History and Analysis
Debt Level: AKRO has more cash than its total debt.
Reducing Debt: AKRO's debt to equity ratio has increased from 0% to 4.7% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AKRO has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: AKRO has sufficient cash runway for 2.9 years if free cash flow continues to reduce at historical rates of 33.7% each year.